Nonclassical monocytes: are they the next therapeutic targets in multiple sclerosis?
Innate immunity is the first line of defense and is rapidly responsive to danger signals from microbial pathogens and tissue injury. The mononuclear phagocyte system encompasses the nongranulocyte population of myeloid cells, which includes circulating blood monocytes, tissue macrophages and dendritic cells.1,2 In this issue, Gjelstrup et al.3 investigate the involvement of various monocyte subsets, particularly the nonclassical monocytes in multiple sclerosis (MS).
|Authors:||Ajami B, Steinman L.|
|Journal:||Immunol Cell Biol. 2018 Feb;96(2):125-127|
|PubMed:||Find in PubMed|